secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001104659-24-038533
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics reports FY 2023 net loss of $8.2M, down from $29.9M; cash runway into Q4 2025
--------------------------------------------------------------------------------

- Net loss narrowed to $8.2M in FY 2023 from $29.9M in FY 2022; R&D spend cut to $10.4M from $12.0M.
- Cash and equivalents $15.1M at Dec 31, 2023; company expects funding into Q4 2025 via grant drawdowns.
- First lymphoma patient treated with MT-601 achieved sustained complete response >6 months after CAR T relapse.
- Completed $19M asset sale to Cell Ready reducing annual overhead ~$11M; secured $2M NIH grant for AML program.
- Appointed Juan Vera as CEO/Principal Financial Officer and Monic Stuart as CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924038533/0001104659-24-038533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924038533/tm249709d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-038533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer